🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Every cancer patient deserves a complete diagnosis.

🚨Detecting cribriform & IDC on MRI-guided prostate biopsy among pts w/ GG2-3 #prostatecancer🚨 👏First-author Raeven Grant (she/her) David Geffen School of Medicine at UCLA just out in ACS Journal Cancer 👉641 pts & 1186 GG2-3 tumors on MRI-guided biopsy 🔬Sensitivity for detecting cribriform, IDC, or either is

Have you checked out the July Podcast? In the newest episode of the podcast Declan Murphy and Nikita Bhatt highlight two key papers from this month's journal, including interviews with key authors. They also catch up with Dr Eoin Dinneen (Melbourne, Australia), who gives a quick

💡 New in #EuropeanUrology: Are we extending life but neglecting quality of life for patients with #bladdercancer, #prostatecancer & #kidneycancer? Marie-Pier St-Laurent , Sarah P. Psutka MD MS, et al. call for better reporting of treatment burden & patient-reported outcomes in GU oncology. 🔗

Local radiotherapy doesn’t improve OS in mHSPC patients, but significantly prolongs time to ADT resistance. Redefining selection criteria is key to identify those who truly benefit in the era of next-generation imaging and modern systemic therapies. sciencedirect.com/science/articl…

Genetic testing is key in suspected inherited #KidneyStones. Test if: 🔹 onset ≤25y 🔹 ≥2 episodes 🔹 bilateral stones 🔹 strong family history Always combine with metabolic tests & pre-test counselling. #EAUguidelines #UroStone #EndoUrology uroweb.org/guidelines/uro…

🔍 Post-void residual (PVR) urine should be measured during the assessment of male LUTS. Although a high PVR may signal poor treatment response, no strict threshold for intervention is established. #EAUguidelines #UroBPH #NeuroUrol uroweb.org/guidelines/man…

Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to Stephen Freedland, MD neal shore & team! Earlier enza works better! Link👉 rb.gy/iyc3f2 OncoAlert UroToday.com Prostate Cancer Foundation

Penile Cancer predominantly affects older individuals, peaking in the sixth decade, particularly in regions with high HPV prevalence, with no known association with HIV or AIDS. #PenileCancer #EAUguidelines uroweb.org/guidelines/pen…

📸 Non-contrast CT is the gold standard for acute flank pain. ✅ Superior to IVU & US ✅ Detects radiolucent stones ✅ Assesses stone density & location 💡 Low-dose CT: high accuracy, less radiation #EAUguidelines #UroStone #EndoUrology uroweb.org/guidelines/uro…

🆕 Check this out! The 2025 #EAUGuidelines on #Urolithiasis are now published in European Urology 📘 🔍 Covering: ✅ State-of-the-art imaging (US, low-dose CT) ✅ MET, ESWL, URS, PCNL ✅ Genetic testing in high-risk patients ✅ Personalized treatment pathways ✅ Practical

📌 Combining α1-blockers with PDE5 inhibitors can modestly improve LUTS, Qmax and erectile function—with no increase in adverse events. Consider for men with bothersome LUTS who also seek ED improvement. #EAUguidelines #UroBPH #ErectileDysfunction uroweb.org/guidelines/man…

Anti-PD-(L)1 immunotherapy is effective in dMMR mCRPC. Best results when dMMR is confirmed by ≥2 tests. Equity in access matters. #prostatecancer #immunotherapy #cancer #oncology European Urology Oncology European Association of Urology (EAU) OncoAlert Prostate Cancer Foundation Advanced Prostate Cancer Consensus Conference Emmanuel Antonarakis aurelius omlin Andrew Armstrong

Just came online in The Lancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh Prostate Cancer Foundation UroToday.com OncoAlert

Consistent & practice-changing! Talazoparib + Enzalutamide improves OS in HRR-deficient mCRPC. OS: 45.1 vs 31.1 months (HR 0.62). BRCA1/2+: 4-year OS 53% vs 23%. A new SoC is here. @asco @oncoalert #prostatecancer #oncology Neeraj Agarwal, MD, FASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 The Lancet Advanced Prostate Cancer Consensus Conference LARVOL

🚨Final results from TALAPRO-2 for advanced #prostatecancer🚨 📜Tandem publications in The Lancet 👉Talazoparib prolonged over all survival for the unselected (HR 0.80) & HRRd populations (HR 0.62) 🔗shorturl.at/v2KMm 🔗shorturl.at/842yQ Prostate Cancer Foundation UroToday.com

Since up to 50% of invasive Penile Cancers and 80% of preneoplastic lesions are HPV-associated, HPV vaccination is encouraged. #PenileCancer #EAUguidelines uroweb.org/guidelines/pen…

J&J receives U.S. FDA Priority Review for TAR-200 in high-risk NMIBC Phase 2b SunRISe-1 study #AUA25 ✅82.4 % CR rate ☑️ 52.9 % cancer-free at least one year after CR jnj.com/media-center/p…

Nanoknife IRE focal therapy, so nice to see this PRESERVE trial finally in print, a monumental and collaborative effort by the Society of Urologic Oncology SUO Clinical Trials Consortium.. a big advancement in care for men with prostate cancer... sciencedirect.com/science/articl… AngioDynamics, Inc.

Novel Therapeutic Strategies for Metastatic Prostate Cancer Care! Alessia Cimadamore Misha Beltran Adam Sharp European Urology European Association of Urology (EAU) Alberto Briganti Advanced Prostate Cancer Consensus Conference OncoAlert #ProstateCancer doi.org/10.1016/j.euru…